Trial Profile
ORENCIA Safety Surveillance in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis (JIA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 15 Jun 2022 Status changed from recruiting to completed.
- 23 Apr 2018 Status changed from not yet recruiting to recruiting.
- 19 Mar 2018 New trial record